EE: Ethinyl estradiol; LNG: Levonorgestrel; OC: Oral contraceptive; RR: Relative risk; VTE: Venous thromboembolism. Transdermal contraceptive patches provide a more convenient delivery system for ...

TWIRLA is indicated as a method of contraception for use in women of reproductive potential with a BMI 30 kg/m2 for whom a combined hormonal contraceptive is appropriate. Limitations of Use Consider ...

Twirla (levonorgestrel and ethinyl estradiol) transdermal system is now available as a method of contraception for use in women of reproductive potential with a BMI Twirla® (levonorgestrel and ethinyl ...

Blood clot risk elevated with contraceptive patches, vaginal rings Women who use the combined contraceptive transdermal patch or vaginal ring are at significantly higher risk for venous thrombosis, ...

The FDA has approved Twirla (levonorgestrel and ethinyl estradiol) transdermal system (Agile Therapeutics) as a method of contraception for use in women of reproductive potential with a body mass ...

Committee Votes 14 to 1, with 1 Abstention, in Favor of Approval PRINCETON, N.J., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, announced a ...

The patch supplies norelgestromin and ethinyl estradiol to the bloodstream through the skin. Has any evidence of genital swelling been documented with the use of the patch when placed inappropriately?

PRINCETON, N.J., June 27, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women’s healthcare company, today announced it has resubmitted to the U.S. Food and Drug Administration ...

(MENAFN- Market Press Release) November 25, 2025 2:59 am - The Transdermal Contraceptive Patches Market, valued at USD 800 million in 2025, is set to grow at a 6% CAGR through 2032. Global Transdermal ...

At the age of 22, Eva Keller started using the patch. Knowing she did not want an invasive contraceptive like an IUD or to have to remember to take a pill every day, Keller opted for a transdermal ...

Agile Says Growing Demand For Twirla (levonorgestrel and ethinyl estradiol ) transdermal system Is Helping It Stay On Track to Hit $25-$30 Million Net Revenue PRINCETON, NJ / ACCESSWIRE / July 3, 2023 ...